A Look At Benzinga Pro's Most-Searched Tickers For June 14

This most-searched list is a feature included in Benzinga Pro's Newsfeed tool. It highlights stocks frequently searched by Benzinga Pro users on the platform.

• ArQule, Inc. ARQL shares were up 31.16% to $8.25 after the company announced clinical proof-of-concept data from its ongoing Phase 1 study of ARQ-531 in patients with relapsed/refractory hematologic malignancies.
• Red Robin Gourmet Burgers, Inc. RRGB shares were volatile Friday. Maxim Group upgraded the stock from Hold to Buy and announced a $49 price target. Vintage Capital on Thursday suggested the company’s board conduct a review of strategic alternatives.
• Fiverr International Ltd. FVRR shares were down 12.99% to $34.50. The stock opened for trade Thursday at $26. The IPO was priced at $21 per share. The stock closed up 90% Thursday.
• Broadcom Inc. AVGO shares were down 6.22% to $264.11 after the company reported worse-than-expected second-quarter sales results and cut 2019 sales guidance below analyst estimates. Charter Equity also downgraded the company's stock from Buy to Market Perform.
• DryShips Inc. DRYS shares were down 4.38% to $3.71. On Thursday, the stock gained 22.8% after SPII offered $4 per share for a merger with the company.
• Coda Octopus Group, Inc. CODA shares were volatile Friday. The company late Thursday reported better-than-expected second-quarter EPS and sales results.
• Legacy Reserves Inc. LGCY shares were up more than 10% to 15 cents after the company reached a global restructuring agreement with RBL Lenders, Second Lien Leaders, and Noteholder Group for its debt.
• India Globalization Capital, Inc. IGC shares were up 44.38% to $1.22 after the company announced late Thursday its subsidiary, Holi Hemp, has been approved to participate in Arizona's industrial hemp program.
• RH RH shares were down 1.24% to 108.50. The stock rose 15.8% Thursday after the company reported better-than-expected first-quarter earnings. The company also raised its 2019 guidance.
• OpGen, Inc. OPGN shares were down 12.27% to 43 cents after the company announced new data that showed clinical utility for antibiotic-resistant urinary tract infection patient management.